Cardiol Clin. 2022 Feb;40(1):13-27. doi: 10.1016/j.ccl.2021.08.002.
ABSTRACT
Pulmonary arterial hypertension is a rare disease characterized by pulmonary microvasculature remodeling leading to right ventricular failure and death. Medical management of pulmonary hypertension has grown increasingly complex as more therapeutic agents have been developed. Evolving treatment strategies leveraging the endothelin, nitric oxide, and prostacyclin pathways lead to improved exercise capacity and outcomes in patients; however, significant opportunities for advancement remain.
PMID:34809914 | DOI:10.1016/j.ccl.2021.08.002